Here we show that Doxil® has minimal antitumour activity in the isolated limb perfusion (ILP) setting and its activity was not enhanced by the addition of tumour necrosis factor (TNF). Doxil® accumulation in tumour tissue was low and also not augmented by TNF. In contrast, activity of free conventional doxorubicin was enhanced by TNF. We conclude that application of Doxil® in a TNF-based ILP is not a useful alternative to free conventional doxorubicin or melphalan.

, , , ,,
British Journal of Cancer
Department of Surgery

ten Hagen, T., Hoving, S., Aan de Wiel-Ambagtsheer, G., van Tiel, S., & Eggermont, A. (2004). Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats. British Journal of Cancer, 90(9), 1830–1832. doi:10.1038/sj.bjc.6601688